Application note: Pushing the boundaries in pharmaceutical hit discovery with the novel waveRAPID® kinetic assay
Posted: 22 June 2021 | Creoptix | No comments yet
We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility.
In this application note, conducted by a high-throughput screening (HTS) drug discovery group from our customer Idorsia Pharmaceuticals Ltd, we demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility. With pulsed injections of each sample at a single concentration, contact times are reduced, preserving target proteins, enabling longer runs and measuring hundreds of interactions in days rather than weeks.
Related content from this organisation
- A multi-step analysis including GCI reveals novel insight into LPS translocation
- Application note: Pushing the boundaries in pharmaceutical hit discovery with the novel waveRAPID® kinetic assay
- The use of biophysical methods in the hit-to-lead process
- Under the microscope: Transforming drug discovery on membrane proteins
Related topics
Assays, Drug Discovery, High-Throughput Screening (HTS), Kinetics, Protein, Targets, Technology
Related organisations
Creoptix
